University of Haifa
haifa.ac.ilTotal trials
96
Active
21
Phase 3
0
Total enrollment
18,409
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Methylphenidate | — | — | — | — | — | 1 | |
| Reboxetine | — | — | — | — | — | 1 |
Next readouts
- 2025-07-01
Top conditions
- Stroke7
- Parkinson Disease5
- Major Depressive Disorder4
- Pelvic Floor Muscle Weakness4
- Mental Health Issue3
- Stress Disorders, Post-Traumatic3
- Stress Related Disorder3
- Healthy3
Frequently asked questions about University of Haifa
- How many clinical trials does University of Haifa have on ClinicalTrials.gov?
- University of Haifa is listed as the lead sponsor on 96 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Haifa's trials are in Phase 3?
- 0 of University of Haifa's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Haifa focus on?
- University of Haifa's most-studied conditions on ClinicalTrials.gov are Stroke, Parkinson Disease, Major Depressive Disorder, Pelvic Floor Muscle Weakness, Mental Health Issue.
- When are University of Haifa's next clinical trial readouts?
- University of Haifa has 1 upcoming primary-completion readout tracked here; the soonest is “Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD”, expected around 2025-07-01.